Salute e Benessere

The 136th Canton Fair: Online Exhibition Platform Empowers Global Digital Trade…

The online platform, which seamlessly integrates supply and source matchmaking, business negotiations, and information sharing, is creating more opportunities for exhibitors to connect with overseas buyers. The 136th Canton Fair has also debuted a virtual digital assistant and a new Canton Fair App that greatly improved trade convenience for exhibitors and buyers. The online platform, which seamlessly integrates supply and source matchmaking, business negotiations, and information sharing, is...
PR Newswire
05/12/2024

VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVADeclaration of shares and voting rightsNovember 30, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: December 5, 2024 Number ofsharescomposing theshare capital of ValnevaTotal numberof voting rights including suspended voting rights*...
Nasdaq GlobeNewswire
05/12/2024

FDA accepts supplemental Biologics License Application for Roche's Columvi…

Application is based on data from the phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival 1,2 This regimen could provide an off-the-shelf, fixed-duration treatment option for patients to start soon after diagnosis, which is important for those who are at high-risk of disease progressionImproving survival outcomes is needed for people with an aggressive disease like relapsed or...
Nasdaq GlobeNewswire
05/12/2024

The 136th Canton Fair: New Quality Productive Forces Driven by Technological…

"The Canton Fair is an important window for China's opening up to the outside world and key platform for foreign trade. From the beginning, agricultural and primary industrial products have been the main exhibits. Now we are also the leading stage for presenting the latest advanced technologies," said Chu Shijia, Deputy Director and Secretary General of the Fair and Director General of China Foreign Trade Centre. "The Canton Fair is an important window forChina'sopening up to the…
PR Newswire
05/12/2024

Leqembi® approved in Mexico

Leqembi's approval is based on data from the large global Phase 3 Clarity AD clinical trial, in which Leqembi met its primary endpoint and all key secondary endpoints with statistically significant results. It is estimated that in Mexico approximately 1.3 million people suffer from Alzheimer's disease.3 Leqembi's approval is based on data from the large global Phase 3 Clarity AD clinical trial, in which Leqembi met its primary endpoint and all key secondary endpoints with statistically...
PR Newswire
05/12/2024

Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed…

DelveInsight provided timely, in-depth analysis of the competitive landscape, emerging therapies, and regulatory situations across multiple countries. This enabled the client to make informed decisions on clinical development, market positioning, and commercialization, helping them stay ahead of the competition in the hematology space. DelveInsight provided timely, in-depth analysis of the competitive landscape, emerging therapies, and regulatory situations across multiple countries. This...
PR Newswire
04/12/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 11/30/2024100,093,87388,576,206 For further information on Cellectis, please contact: Media contact:Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Sosa Navarro, Chief of Staff to the CEO, +33...
Nasdaq GlobeNewswire
04/12/2024

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on…

Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 4898380 Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871 Ireland Dial-In Number: +353 1800 943 926 Additional global dial-in numbers are availablehere. Passcode: 4898380 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at...
PR Newswire
04/12/2024

Spineway carries out a capital reduction by reducing the par value of its shares

Press release Ecully, December 4, 2024 – 8 p.m. CETSpineway carries out a capital reduction by reducing thepar value of its shares The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that the Board of Directors of Spineway (the “ Company ”) decided at its meeting of December 4, 2024, acting on a delegation of authority granted by the Combined General Meeting of March 25, 2024, under the terms of its twenty-third...
Nasdaq GlobeNewswire
04/12/2024

RNA Sequencing: Transforming Genomics and Shaping Future Markets

This research report explores the global RNA sequencing market, providing an analysis of its trends and projections through 2029. It breaks down the market by product, technology, application, end user, and region, The regions are North America, Europe, Asia-Pacific and the Rest of the World. This research report explores the global RNA sequencing market, providing an analysis of its trends and projections through 2029. It breaks down the market by product, technology, application, end user,...
PR Newswire
04/12/2024

Global IVD Reagents Market to Reach USD 55.3 Billion by 2029: Key Drivers and…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-13I16127/Global_and_India_In_Vitro_Diagnostic_IVD_Reagents Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-13I16127/Global_and_India_In_Vitro_Diagnostic_IVD_Reagents Major Factors Driving the Growth of IVD Reagents Market: The IVD reagents market is thriving, driven by the rising prevalence of chronic and infectious diseases, growing focus on preventive healthcare, and advancements in...
PR Newswire
04/12/2024

Safe Group - Distribution contract signed with Wenzel

Distribution contract signed with WenzelFleurieux-sur-l'Arbresle-France – December 4, 2024 at 6 p.m.Safe SA (la « Société ») announces thesigning of strategic agreementsbetween Safe Orthopaedics, a pioneer in ready-to-use technologies for spinal column pathologies, andWenzelSpine, a US company specializing in the development of minimally invasive surgical technology and analytical platforms for the treatment of spinal disorders, is notably known for its range of...
Nasdaq GlobeNewswire
04/12/2024

Viral Vaccines Market to be Worth $64.18 Billion by 2031 - Exclusive Report by…

Download FREE PDF Brochure Of Viral Vaccines Market - Download FREE PDF Brochure Of Viral Vaccines Market - https://www.meticulousresearch.com/download-sample-report/cp_id=5920 Viral vaccines or viral vector vaccines use a viral vector to deliver genetic material into the host to elicit an immune response to fight or protect against viral infections. The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine...
PR Newswire
04/12/2024

Kegel Exercise Device Market Booms: Biofeedback Tech Leads the Way | Valuates…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-29C12397/Global_Kegel_Exercise_Device_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-29C12397/Global_Kegel_Exercise_Device_Market Major Factors Driving the Growth of Kegel Exercise Device Market: The Kegel Exercise Device Market is experiencing significant growth, driven by rising awareness about pelvic health and the increasing prevalence of pelvic floor disorders such as urinary...
PR Newswire
04/12/2024

Human Organoids Market to Hit USD 2.33 Billion by 2029 with 14.4% CAGR |…

Browse in-depth TOC on "Human Organoids Market" Browse in-depth TOC on "Human Organoids Market" 543 - Tables 51 - Figures 426 - Pages The market is gaining more attention in human organoids amid the major technological developments, new regulatory requirements, and growing demand for alternatives of animal models. For instance, in 2022, the FDA Modernization Act 2.0 came into effect, which permitted the FDA to consider data outside of the classical conduct of animal…
PR Newswire
04/12/2024

The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities Issued…

Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare, today announced it has entered into a strategic alliance with global biotech giantRoche Holding AG(OTCQX: RHHBY, RHHVF), and leading pre-paid health plan...
PR Newswire
04/12/2024

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab…

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)40,000 new wet AMD patients each year in the UK who could benefit from treatment 1ISELIN, N.J., Dec.04, 2024(GLOBE NEWSWIRE) --Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company that achieved...
Nasdaq GlobeNewswire
04/12/2024

Coloplast divests core Skin Care product portfolio

The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin.Coloplast's FY 2024/25 financial guidance 1of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the...
Nasdaq GlobeNewswire
04/12/2024

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary…

Additional trial sites include: Yale UniversityJohns Hopkins UniversityCornell UniversityUniversity at Buffalo (SUNY)University of Massachusetts (UMass)Thomas Jefferson UniversityThese universities represent leaders in medical research and neurology, with a history of pioneering studies in multiple sclerosis. Their inclusion enhances the trial's reach and brings together top-tier expertise with innovative facilities to evaluate Tiziana's promising approach to...
Nasdaq GlobeNewswire
04/12/2024

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S…

"This all-in-one, first-of-its-kind catheter allows physicians to map, ablate and validate all with a single catheter, enhancing workflow flexibility and efficiency, ultimately enabling greater safety and efficacy," Dr. Natale said. "As global innovation for the treatment of heart arrhythmias continues to advance, the Texas Cardiac Arrhythmia Institute is grateful to be leading the way for patients in Central Texas and beyond." "This all-in-one, first-of-its-kind…
PR Newswire
04/12/2024

Fragrance Ingredients Market worth $21.94 billion by 2029 - Exclusive Report by…

Additionally, according to leading fragrance company Givaudan, 74% of consumers associate well-being with mental and emotional health, highlighting fragrance's role in enhancing overall wellness. Additionally, according to leading fragrance company Givaudan, 74% of consumers associate well-being with mental and emotional health, highlighting fragrance's role in enhancing overall wellness. Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105416890 ...
PR Newswire
04/12/2024

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for…

Floris van Delft, Head of Research and Development at Synaffix, said: "At Synaffix, we are deploying a superior probe, bicyclononyne (BCN), for metal-free click chemistry for the highly selective generation of site-specific and stable antibody-drug conjugates for targeted treatment of cancer. There are also many other therapeutic applications and beyond, such as diagnostics and materials science, that can benefit from the unique chemical coupling properties of BCN. This transaction with…
PR Newswire
04/12/2024

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT NOVEMBER 2024

Accumulated revenue for January – November 2024 increased by 21 % to SEK 1955.9 (1611.0) million. Accumulated revenue for January –November 2024increased by 21 % toSEK 1955.9(1611.0) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &...
PR Newswire
04/12/2024

Antag Therapeutics Announces €80 Million Series A Financing

COPENHAGEN, Denmark, Dec. 4, 2024 /PRNewswire/ -- Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO). The funds will support the…
PR Newswire
04/12/2024
Altri  Comunicati